Pre-made Lemalesomab benchmark antibody (Whole mAb, anti-NCA-90 (nonspecific cross- reacting antigens 90kDa glycoproteins, granulocyte cell antigen) [human] therapeutic antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-NCA-90 (nonspecific cross- reacting antigens 90kDa glycoproteins, granulocyte cell antigen) [human] therapeutic antibody (Pre-made Lemalesomab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lemalesomab is a mouse monoclonal antibody for the diagnosis of inflammatory lesions.[1][2]
| Products Name (INN Index) | Pre-Made Lemalesomab Biosimilar, Whole Mab: Anti-Nca-90 (Nonspecific Cross- Reacting Antigens 90Kda Glycoproteins, Granulocyte Cell Antigen) [human] therapeutic antibody |
|---|---|
| INN Name | lemalesomab |
| Target | NCA-90 (nonspecific cross- reacting antigens 90kDa glycoproteins, granulocyte cell antigen) [Homo sapiens] |
| Format | Whole mAb |
| Derivation | Mus musculus |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 – nd |
| VD LC | IgG1 – nd |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | NA |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | NCA-90 (nonspecific cross- reacting antigens 90kDa glycoproteins, granulocyte cell antigen) [Homo sapiens] |
| Package |
